Clinical Trial Update: IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluates enasidenib as maintenance therapy for IDH2-mutant myeloid neoplasms after allogeneic stem cell transplantation. The study status is CO…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelomonocytic Leukemia

Drugs mentioned

• IDHIFA (enasidenib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 1 | Status: COMPLETED